North American Cannabis Holdings Previews Official AmeriCanna Cafe Launch Event and Pending New Strategic Acquisition
Company Publishes Online On-Demand Update Presentation
DALLAS, March 10, 2017
DALLAS, March 10, 2017 /PRNewswire/ —
Puration, Inc. (USOTC: PURA) and North American Cannabis Holdings, Inc. (USOTC: USMJ) today published a joint online, on-demand presentation. PURA’s operation is a spinoff from USMJ and the two companies work closely together with PURA producing EVERx CBD Infused Water under a license from USMJ. The presentation previews an upcoming announcement on an USMJ official AmeriCanna Cafe launch event, and a pending transformational acquisition. USMJ and PURA management also address recent President Trump administration remarks regarding state by state marijuana legalization. The presentation includes updates on progress to date toward the USMJ $2 million revenue forecast and the PURA $3 million revenue forecast. Furthermore, the presentation includes updates on USMJ’s ongoing progress to launch a retail cannabis payment system with Alternet Systems, Inc. (USOTC: ALYI) in a transaction to include a dividend of ALYI stock to USMJ shareholders. Additionally, the presentation includes an update on PURA’s transaction with Spanish Peaks ScrumpDelicacies and ML Capital Group (USOTC: MLCG) and the planned issue of ScrumpDelicacies stock in a dividend distributions to PURA and MLCG shareholders.
See the online On-demand Presentation Now
To learn more about Puration: purationinc.com
To learn more about North American Cannabis Holdings: growusmj.com.
Disclaimer/Safe Harbor: This news release contains forward-looking statements within the meaning of the Securities Litigation Reform Act. The statements reflect the Company’s current views with respect to future events that involve risks and uncertainties. Among others, these risks include the expectation that any of the companies mentioned herein will achieve significant sales, the failure to meet schedule or performance requirements of the companies’ contracts, the companies’ liquidity position, the companies’ ability to obtain new contracts, the emergence of competitors with greater financial resources and the impact of competitive pricing. In the light of these uncertainties, the forward-looking events referred to in this release might not occur. These statements have not been evaluated by the Food and Drug Administration. These products are not intended to diagnose, treat, cure or prevent any disease.